# Matthew D. Hellmann

Source: https://onco.cc/people/matthew-hellmann/  
OnCo record `matthew-hellmann` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Lung cancer doctor who was the lead author of CheckMate 227, the trial that showed the immunotherapy pair nivolumab and ipilimumab helps people with advanced lung cancer live longer than chemotherapy alone.

## Summary

Matthew Hellmann was first author of the CheckMate 227 reports in the New England Journal of Medicine, including the 2019 overall-survival analysis of nivolumab plus ipilimumab in previously untreated advanced non-small-cell lung cancer. His research at Memorial Sloan Kettering Cancer Center, where he practised as a thoracic oncologist, centred on tumour mutational burden and other predictors of response to immune checkpoint blockade.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: lung; immunotherapy; trialist
- Role: Medical oncologist and trial lead, thoracic immunotherapy
- Specialisms: Non-small-cell lung cancer; Immune checkpoint inhibitors; Tumour mutational burden

## Connected records

- cancers: [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [PD-L1-high non-small-cell lung cancer without a driver mutation](https://onco.cc/cancers/pdl1-high-nsclc/)
- trials: [CheckMate 227](https://onco.cc/trials/checkmate-227/)

---
JSON: https://onco.cc/api/v1/entities/matthew-hellmann.json